Biologics Market - By Type: Monoclonal Antibodies, Vaccines, Recombinant Proteins, Gene Therapies, Cell Therapies. By Application: Cancer, Cardiovascular Diseases, Autoimmune Diseases, Infectious Diseases. By End-user: Hospitals, Clinics, Biotech Companies, Pharmaceutical Companies. By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The global biologics market was valued at USD 421.5 billion in 2023 and is projected to reach USD 856.3 billion by 2031, growing at a CAGR of 9.3%. This growth is driven by the increasing demand for targeted therapies, advancements in biotechnology, and the rising prevalence of chronic diseases. Key segments include monoclonal antibodies, vaccines, and cell & gene therapies.
2024 Market Breakthroughs
1. Next-Generation Biologics
2. Manufacturing Innovations
3. Regulatory Advancements
Market Drivers
Competitive Landscape
|
Company |
Market Share |
Flagship Product |
2024 Pipeline |
|
Roche |
22% |
Rituxan® |
15 oncology biologics |
|
AbbVie |
18% |
Humira® |
8 immunology biosimilars |
|
Novartis |
15% |
Cosentyx® |
10 cell & gene therapies |
Emerging Disruptors:
Market Segmentation
Recent Developments (2024)
Need help?
Chat with our team in a minute.